Vose JM - Search Results

1

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.

Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Among authors: vose jm. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.

2

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up.

Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, Frappier B, Schmit-Pokorny K, Weisenburger DD, Armitage JO. Vose JM, et al. Blood. 1992 Oct 15;80(8):2142-8. Blood. 1992. PMID: 1356515 Free article.

3

Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents.

Gordon BG, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE, Anderson JR, Verdirame JD, Bierman PJ, Armitage JO, et al. Gordon BG, et al. Among authors: vose jm. Blood. 1992 Dec 1;80(11):2938-42. Blood. 1992. PMID: 1450419 Free article.

4

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.

Kessinger A, Bierman PJ, Vose JM, Armitage JO. Kessinger A, et al. Among authors: vose jm. Blood. 1991 Jun 1;77(11):2322-5. Blood. 1991. PMID: 1674890 Free article.

5

Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.

Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Bashir RM, et al. Among authors: vose jm. Am J Clin Oncol. 1991 Dec;14(6):478-82. doi: 10.1097/00000421-199112000-00004. Am J Clin Oncol. 1991. PMID: 1720278

6

Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.

Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Reed EC, Vaughan WP, Coccia PF, Purtilo DT. Armitage JO, et al. Among authors: vose jm. Am J Med. 1991 Dec;91(6):605-11. doi: 10.1016/0002-9343(91)90213-h. Am J Med. 1991. PMID: 1750430

7

Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas.

Vose JM, Peterson C, Bierman PJ, Weisenburger DD, Linder J, Harrington D, Vaughan WP, Kessinger A, Armitage JO. Vose JM, et al. Blood. 1990 Jul 15;76(2):424-31. Blood. 1990. PMID: 1973361 Free article.

8

The present status of therapy for patients with aggressive non-Hodgkin's lymphoma.

Vose JM, Armitage JO. Vose JM, et al. Ann Oncol. 1991 Feb;2 Suppl 2:171-6. doi: 10.1007/978-1-4899-7305-4_27. Ann Oncol. 1991. PMID: 2049315 Free article. Review.

9

Salvage therapy for patients with non-Hodgkin's lymphoma.

Armitage JO, Vose JM, Bierman PJ. Armitage JO, et al. Among authors: vose jm. J Natl Cancer Inst Monogr. 1990;(10):39-43. J Natl Cancer Inst Monogr. 1990. PMID: 2189475 Review.

10

The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.

Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, et al. Vose JM, et al. J Clin Oncol. 1988 Dec;6(12):1838-44. doi: 10.1200/JCO.1988.6.12.1838. J Clin Oncol. 1988. PMID: 2462026

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

518 results

Search Page